Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca

Interim recommendations from the WHO’s SAGE panel recommend the vaccine can be widely used, including in people aged over 65, and should be given in a two-dose regimen, with each dose given with an interval of around eight to 12 weeks.

Source:

World Health Organization